DexCom (DXCM) Tops Q3 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
DexCom (DXCM) PT Raised to $655 at Jefferies
October 29, 2021 7:43 AM EDTJefferies analyst Raj Denhoy raised the price target on DexCom (NASDAQ: DXCM) to $655.00 (from $610.00) while maintaining a Buy rating.
The analyst commented, "XCM posted a $31mn/$0.25 beat on accelerating T2 adoption and OUS momentum which was supplemented by G&A leverage gains.... More
